Long-term use of AndroGel®, a
transdermal testosterone replacement gel, is safe and effective in men with
low testosterone up to 42 months
San Francisco, Calif. and Torrance, Calif.
(June 20, 2002) A Phase 3 study conducted at multiple research centers in
the U.S. under the direction of Ronald Swerdloff, MD, Principal Investigator
at the Research and Education Institute at Harbor-UCLA Medical Center (REI)
shows that long-term use of AndroGel®, a transdermal testosterone
replacement gel, is safe and effective in men with low testosterone.
Scientists reported their results today at
the 84th Annual Meeting of The Endocrine Society.
"This study represents a new milestone
in the treatment of men with low testosterone," said Christina Wang,
MD, REI Investigator in the Division of Endocrinology, Metabolism &
Nutrition and Director, Harbor-UCLA General Clinical Research Center.
"It is the first study to demonstrate that long-term use of
testosterone gel replacement is both safe and effective.
Because hypogonadism requires continuous
treatment, it is important to understand the effects of testosterone
replacement therapy over an extended period of time."
The U.S. Food and Drug Administration (FDA)
estimates that four to five million American men have low testosterone, but
only about five percent are currently treated. It is also estimated that low
testosterone affects about one in 10 men between the ages of 40 and 60 and
more than two in 10 men over the age of 60. Low testosterone, also called
hypogonadism, is linked with conditions such as diminished interest in sex,
erectile dysfunction (ED), osteoporosis, reduced lean body mass, depressed
mood and fatigue.
In the trial, led by REI investigators, 92
hypogonadal men, with an average age of 52, received continuous replacement
with testosterone gel for up to 42 months (average 29 months). Initially,
each man was treated with one percent testosterone gel (AndroGel®) at 5 or
10 grams per day, with a dose adjustment to 7.5 grams per day in some men at
three months to maintain testosterone levels in a normal range. There were
no significant differences in age, ethnicity, body weight or height among
the groups receiving different amounts of AndroGel®. AndroGel® is
manufactured by Unimed Pharmaceuticals, Inc., a wholly owned, independently
operated subsidiary of Solvay Pharmaceuticals, Inc.
The study showed that sexual motivation and
performance significantly improved in men receiving testosterone gel at six
months and this was maintained throughout treatment. Fat mass continued to
decrease over the course of the treatment period (with an average decrease
of 2.5 kilograms, or 5.5 pounds, at 30 months) and lean (nonfat) body mass,
increased (with an average increase of 3.5 kilograms, or 7.7 pounds, at 30
months). Bone mineral density also increased by six months and remained
significantly increased by about 4% in the spine and 2% in the hip at 30
months of treatment. . Daily application of the testosterone replacement gel
only caused minimal skin irritation. There were minimal other side effects.
Citation: an article
published on the Internet by EurekaAlert 2002 <http://www.eurekalert.org/...002.php>
